Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human REV3L protein cleavage inhibitor and application thereof

A technology of inhibitors and active inhibitors, which can be used in peptide/protein components, animal/human peptides, DNA/RNA fragments, etc., and can solve problems such as tumor recurrence and drug resistance

Inactive Publication Date: 2020-07-31
CAPITAL NORMAL UNIVERSITY
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] In cancer treatment, many chemotherapeutic drugs are effective at the beginning, but drug resistance will develop after a long time, leading to tumor recurrence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human REV3L protein cleavage inhibitor and application thereof
  • Human REV3L protein cleavage inhibitor and application thereof
  • Human REV3L protein cleavage inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Confirmation of post-translational cleavage-dependent sequence elements

[0034] After inserting a FLAG tag coding sequence in the 5' upstream of the endogenous REV3L gene coding region in human HCT116 cells, it was found that a protein with a FLAG tag of about 70 kDa was expressed in the cells. After identification by anti-FLAG immunopurification coupled to mass spectrometry under denaturing conditions, it was finally confirmed that the 70 kDa protein with FLAG tag was REV3L protein with C-terminal deletion.

[0035] Using transient expression of a series of REV3L deletion mutants with N-terminal and C-terminal fusions of FLAG and HA tags in HEK293 cells, it was found that the 70kDa C-terminal deletion REV3L protein was generated by a site-specific post-translational protein cleavage event , and the cleavage product was named REV3L-N70, and its amino acid sequence is shown in SEQ ID No.5.

[0036] Through further expression experiments of deletion mutants an...

Embodiment 2

[0037] Example 2 Verifies the relationship between sequence elements, protease TASP1 and human REV3L protein

[0038] In human HEK293 cells expressing the REV3L N-terminal fragment containing the QLDGTAD cleavage sequence, overexpression of wild-type TASP1 can significantly increase the protein cleavage efficiency of the REV3L N-terminal fragment. At the same time, overexpression of TASP1-T234A mutant (TASP1-Mut) without protease activity has no corresponding effect.

[0039] A stable cell line expressing the N-terminal fragment of REV3L containing the QLDGTAD cleavage sequence was constructed in HeLa cells. In this cell line, TASP1 expression was reduced by siRNA-mediated RNA interference. The result is as figure 1 As shown in A, cleavage of the REV3L N-terminal fragment was significantly inhibited.

[0040] ShRNA-mediated RNA interference reduces TASP1 expression in human colon cancer-derived HCT116 cells. The result is as figure 1 As shown in middle B, the cleavage pro...

Embodiment 3

[0042] Example 3 Effect of post-translational sequence-dependent cleavage of REV3L by TASP1 protease on REV3L protein stability and DNA polymerase ζDNA synthesis activity

[0043] Using the CRISPR / Cas9-mediated homologous recombination strategy, a site-directed mutation was introduced into the endogenous REV3L gene of human rectal cancer cell HCT116, resulting in alanine substitution in the cleavage-dependent sequence element of the REV3L mutant encoded by it, resulting in expression cleavage Mutant cell lines deficient in the REV3L-Mut protein. The changes in the REV3L gene sequence in the mutant cells were verified by genomic DNA sequencing. The effect of mutation on REV3L protein cleavage was verified by Western blot.

[0044] 1. Uncleaved full-length human REV3L protein can undergo proteasome-mediated protein degradation through K48-polyubiquitination

[0045] a) Comparison of cleavage-deficient REV3L-Mut mutant cells and wild-type cells, such as figure 2 As shown in A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biomedicine, and particularly relates to a human REV3L protein cleavage inhibitor and application thereof. The invention discloses a drug for improvingsensitivity of tumor cells to DNA damage and controlling drug resistance of tumor cells. The action target of the drug is obtained by a protease TASP1 mediated human REV3L protein position specific cleavage event. The inventor finds that the human REV3L protein has a TASP1 mediated sequence dependent protein cleavage event; polyubiquitination modification of REV3L protein and proteasome mediated degradation can be effectively promoted by interfering the REV3L protein cleavage event, so that low-fidelity cross-damage DNA synthesis activity in tumor cells is further reduced, DNA mutation inducedby DNA damage is reduced, sensitivity of tumor cells to DNA damage is remarkably improved, and therefore, a new potential drug target is provided for enhancing the radiotherapy and chemotherapy effects of tumors and other diseases taking induction of DNA damage as a molecular basis and controlling generation of drug resistance.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an inhibitor of human REV3L protein cleavage and an application thereof. Background technique [0002] In tumor treatment, many chemotherapeutic drugs are effective at the beginning, but drug resistance will develop after a long time, leading to tumor recurrence. The secondary drug resistance of tumor cells has become the main reason for the failure of tumor chemotherapy. With the development of whole-genome sequencing of tumor cells, it is gradually recognized that genomic changes, mainly in the form of DNA mutations, are the molecular basis of acquired chemotherapy resistance. [0003] Low-fidelity translesion DNA synthesis is an important source of DNA mutations. DNA polymerase ζ is the main polymerase involved in low-fidelity cross-lesion DNA synthesis in eukaryotic cells, and its catalytic subunit REV3L loses the proofreading function due to the lack of 3' ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/7105A61K31/285A61K38/02A61K45/06A61K33/243A61P35/00
CPCA61K31/285A61K31/7105A61K33/24A61K38/02A61K45/00A61K45/06A61P35/00A61K2300/00A61K38/17A61K33/243C07K14/47C12N15/11C12Q1/68G01N33/68
Inventor 李夏璐王凤亭李苗苗
Owner CAPITAL NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com